Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2024-02-26 00:00:00 ET · period of report 2024-02-22 · accession 0001628280-24-006985 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-26 | 2024-02-22 | VIR | HANLY ANN M. | EVP, CTO | S - Sale | $10.05 | -12.3K | 134.8K | -8% | -$123.6K |
| D | 2024-02-26 | 2024-02-22 | VIR | HANLY ANN M. | EVP, CTO | A - Grant | $0.00 | +32.5K | 147.1K | +28% | $0 |
| D | 2024-02-26 | 2024-02-22 | VIR | HANLY ANN M. | EVP, CTO | A - Grant | $0.00 | +65.0K | 65.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-22 | S | D | 12,296 | $10.05 | 134,780 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-22 | A | A | 32,500 | $0.00 | 147,076 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-02-22 | A | A | 65,000 | $0.00 | 65,000 | D | $10.11 · — to 2034-02-21 | 65,000 Common Stock | (F4) 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter. |